Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLG | P00747 | 1/20 | 0.44 |
| ▸ | PLAT | P00750 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | GABRA5 | P31644 | 3/20 | 0.41 |
| ▸ | GABRB2 | P47870 | 3/20 | 0.41 |
| ▸ | SLC6A1 | P30531 | 2/20 | 0.41 |
| ▸ | SLC6A12 | P48065 | 2/20 | 0.41 |
| ▸ | SLC6A11 | P48066 | 2/20 | 0.41 |
| ▸ | SLC6A13 | Q9NSD5 | 2/20 | 0.41 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.41 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.41 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.41 |
| ▸ | CPN1 | P15169 | 2/20 | 0.40 |
| ▸ | CPB2 | Q96IY4 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | GABRP | O00591 | 1/20 | 0.39 |
| ▸ | GABRD | O14764 | 1/20 | 0.39 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.39 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.39 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL3451505 | 0.89 | SLC6A1 (0.52) | PLGPLATLMNAGABRA5GABRB2 | |
| Trifluoroacetic Acid SCHEMBL13254840 | 0.87 | GABRA5 (0.40) | GABRA5GABRB2SLC6A1SLC6A12SLC6A11 | |
| Pivalate SCHEMBL28006783 | 0.85 | PLG (0.44) | PLGPLATLMNAGABRA5GABRB2 | |
| Trifluoroacetic Acid SCHEMBL13254839 | 0.81 | GABRA5 (0.43) | GABRA5GABRB2SLC6A1SLC6A12SLC6A11 | |
| Trifluoroacetic Acid SCHEMBL38661436 | 0.81 | GABRA5 (0.41) | GABRA5GABRB2SLC6A1SLC6A12SLC6A11 | |
| Trifluoroacetic Acid SCHEMBL23044797 | 0.79 | GABRA5 (0.40) | GABRA5GABRB2SLC6A1SLC6A12SLC6A11 | |
| Trifluoroacetic Acid SCHEMBL29890740 | 0.79 | ITGB3 (0.49) | GABRA5GABRB2SLC6A1SLC6A12SLC6A11 | |
| Trifluoroacetic Acid SCHEMBL20494145 | 0.79 | GABRA5 (0.53) | GABRA5GABRB2SLC6A1SLC6A12SLC6A11 | |
| Trifluoroacetic Acid SCHEMBL29163766 | 0.79 | GABRA5 (0.53) | GABRA5GABRB2SLC6A1SLC6A12SLC6A11 | |
| Trifluoroacetic Acid SCHEMBL28325251 | 0.79 | GABRA5 (0.53) | GABRA5GABRB2SLC6A1SLC6A12SLC6A11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2536731-A1 | SUBSTITUTED SPIROINDOLINONES | F. Hoffmann-La Roche AG (CH) | 2012-12-26 | — | — | EP | claimed |
| US-8288431-B2 | Substituted spiroindolinones | HOFFMANN-LA ROCHE INC. (US) | 2012-10-16 | — | — | US | claimed |
| EP-2536731-A1 | SUBSTITUTED SPIROINDOLINONES | F. Hoffmann-La Roche AG (CH) | 2012-12-26 | — | — | EP | disclosed |
| US-8288431-B2 | Substituted spiroindolinones | HOFFMANN-LA ROCHE INC. (US) | 2012-10-16 | — | — | US | disclosed |
| EP-1878725-B1 | Pyrimidine derivatives and their use as CB2 modulators | GLAXO GROUP LTD (GB) | 2010-11-24 | — | — | EP | disclosed |
| US-20100041654-A1 | Pyrimidine Derivatives And Their Use As CB2 Modulators | EATHERTON ANDREW JOHN | 2010-02-18 | — | — | US | disclosed |
| US-7635701-B2 | Pyrimidine derivatives and their use as CB2 modulators | GLAXO GROUP LIMITED (GB) | 2009-12-22 | — | — | US | disclosed |
| EP-1878725-A2 | Pyrimidine derivatives and their use as CB2 modulators | GLAXO GROUP LIMITED (GB) | 2008-01-16 | — | — | EP | disclosed |
| US-20060293354-A1 | Pyrimidine derivatives and their use as CB2 modulators | GLAXO GROUP LIMITED (GB) | 2006-12-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060293354-A1 | Pyrimidine derivatives and their use as CB2 modulators | CNR2, CNR1, P2RX3 | PLG 4533/4885PLAT 2613/4885LMNA 4159/4885 |
| US-20100041654-A1 | Pyrimidine Derivatives And Their Use As CB2 Modulators | CNR2, CNR1, P2RY2 | PLG 4446/4885PLAT 2678/4885LMNA 4114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.